MINSPOM-MIMICSNCT07694453
PeriOperative Medicine - Metabolic Inflexibility as a Mechanism for Myocardial Injury After Non-Cardiac Surgery
An observational study of MINS, run by University College, London.
Trial summary
The goal of this observational study is to learn whether metabolic inflexibility, which means reduced ability of the body to switch between using fats and sugars for energy, is associated with myocardial injury after non-cardiac surgery (MINS) in adults undergoing major elective abdominal cancer surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- MINS
- What is being tested?
- Pre-operative Metabolic Inflexibility
- How many people
- 300 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 1 Oct 2030
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants will be selected from patients receiving care at University College London Hospitals and other participating CIPHER-2 network hospitals, including Southampton and Plymouth. Potential participants will be identified through perioperative/pre-operative assessment pathways, including routine cardiopulmonary exercise testing clinics for patients being assessed before major surgery.
Who may be able to join
- Adults aged 18 or over
- Scheduled for major elective abdominal cancer surgery with planned overnight admission
- Scheduled for pre-operative CPET
- Able to provide written informed consent
Who cannot join
- Less than 18 years old
- Emergency surgery
- Unable or unwilling to undergo CPET
- Pregnancy
- Active sepsis
- End-stage organ failure (e.g. on dialysis)
- Participants without the mental capacity to consent
- Diagnosis of Type 1 Myocardial Infarction meeting the 4th Universal Definition criteria during the immediate pre-operative period. (Note: Added based on MINS definition context)
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this observational study is to learn whether metabolic inflexibility, which means reduced ability of the body to switch between using fats and sugars for energy, is associated with myocardial injury after non-cardiac surgery (MINS) in adults undergoing major elective abdominal cancer surgery.
The main question it aims to answer is:
Read more
Does pre-operative metabolic inflexibility predict myocardial injury after non-cardiac surgery (MINS) within the first 72 hours after surgery?
Participants will continue with their usual surgical care and pre-planned CPET (which can measure metabolic flexibility). As part of the study, participants will:
- Have additional blood samples taken before and after surgery
- Have an echocardiogram and, where possible, muscle ultrasound
- Wear a wrist-worn activity monitor before surgery
- Have routine clinical and surgical information collected from their medical records
- Receive a follow-up phone call around 90 days after surgery
Read the detailed description
The POM-MIMIC study (PeriOperative Medicine - Metabolic Inflexibility as a mechanism for Myocardial Injury after Non-Cardiac Surgery) is a prospective, observational cohort study designed to improve perioperative risk stratification for myocardial injury after non-cardiac surgery (MINS). MINS affects up to 25% of patients undergoing major surgery and significantly increases long and short term mortality (1). Despite its clinical importance, the ability to predict MINS remains limited.
This study aims to evaluate if perioperative metabolic inflexibility, (the impaired ability of cells to adapt fuel usage to demand), is a driver of MINS. The study hypothesises that systemic metabolic dysfunction creates a state of cardiac vulnerability, priming the heart for injury when exposed to the multi-faceted immune/inflammatory and haemodynamic stressors of surgery and anaesthesia.
This study involves a prospective, multicentre observational cohort study of patients undergoing major abdominal cancer surgery. The study investigators will employ a deep, multi-modal phenotyping strategy to characterise each patient's intrinsic "metabolic resilience phenotype", with the goal of describing novel endotypes of MINS. The investigators propose that the endotypes of MINS are:
Immune mediated / inflammatory endotype: Driven by pre-existing inflammation and perioperative immune dysregulation
Metabolic / proteomic endotype: Driven by metabolic inflexibility and may involve direct metabolic injury to cardiomyocytes, lipotoxicity, oxidative stress, and unique troponin fragment signatures
Type II MI / Ischaemic-dominant endotype: Classic supply-demand mismatch (e.g. from intraoperative hypotension), likely amplified in metabolically vulnerable hearts
Mixed phenotype: A combination of the above, reflecting the interaction of metabolic, immune, and haemodynamic stressors
The phenotyping strategy will integrate:
Functional assessment: Cardiopulmonary exercise testing (CPET) to quantify metabolic flexibility via substrate utilisation
Structural assessment: Advanced imaging (CT/ultrasound) to quantify body composition, including myosteatosis and cardiac steatosis, which are markers of metabolic vulnerability
Biological assessment: High-dimensional immunophenotyping, targeted proteomics to identify novel troponin sub-fragment signatures which may reveal if injury is ischaemic, metabolic, or inflammatory, as well as in vitro studies using patient serum on human IPSC-derived cardiomyocytes to test for direct metabotoxicity
An exploratory outcome of reviewing intra-operative data for hypotension, anaesthetic type, and haemodynamics will assess for the ischaemic phenotype.
The study will recruit 300 adult patients undergoing major elective abdominal cancer surgery at UCLH and participating CIPHER-2 sites (Southampton and Plymouth). Participants will undergo routine pre-operative CPET. CPET analysis will derive VO2 peak, anaerobic threshold, metabolic crosscover and substrate utilisation metrics (fat vs carbohydrate oxidation) - the operational measure of metabolic flexibility. They will also undergo routine echocardiography and ultrasound . At this time blood sampling will be taken for targeted and untargeted metabolomics / lipidomics, biobanking of plasma/serum and PBMCs for immunophenotyping. Intra-operatively, haemodynamic monitoring as well as anaesthetic technique will be recorded. Post-operatively, hs-cTnI will be taken on days 1, 2, and 3 to assess for MINS. On days 1, 3, and 5 blood will be taken for biobanking of plasma/serum and PBMCs for immunophenotyping. On day 1 additional biomarker sampling at 24 hours will assess proteomic troponin fragmentation analysis and for mass spectrometry. Outcomes of interest include the incidence of MINS, post operative complications, length of hospital stay, and 90-day recovery metrics. See figure 1 for the participant pathway. A mechanistic substudy (n=150) will investigate inflammatory and immune profiles to explore underlying biological drivers of cardiac susceptibility to stress, these tests will utilise the blood taken for biobanking on days 1, 3, and 5. A further substudy (n=150) will assess if changes in high sensitivity troponin (hs-cTnI levels) measured before and 2 hours after CPET, are associated with the incidence of MINS. An exploratory aim of the project will be to review if there is an association between pre- and post-operative wearable signals (such as activity and heart rate) and MINS. See figure 2 for the conceptual framework of the study.
The data from samples from the MIMICS study will power four interconnected work packages:
WP1 - Immune / inflammatory predictors of MINS (n=150 sub-cohort serum samples)
WP2 - Machine learning integration for MINS prediction
WP3 - Cellular mechanisms and preclinical validation (n=150 sub-cohort serum samples)
WP4 - Targeted proteomic analysis of troponin fragmentation
Through the findings of POM-MIMIC the study investigators hope to redefine understanding of MINS by identifying endotypes. This could lead to immediate clinical benefits by enhancing preoperative risk models through integration of CPET, imaging, and blood testing. These are feasible non-invasive tests that could be rapidly adopted into standard preoperative assessments. This study has translational value as once endotype is categorised, targeted therapies which have been proven to work (such as prehabilitation for metabolic inflexibility) can be employed to reduce perioperative complications and improve outcomes. On a broader scale, this work may inform policy on perioperative cardiac care and guide future clinical trials.
- Conditions
- MINS
- Being tested
- Pre-operative Metabolic Inflexibility
- Keywords
- MINS, metabolic flexibility, CPET, Cardiopulmonary Exercise Testing, abdominal cancer surgery, Perioperative medicine, Troponin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pre-operative Metabolic InflexibilityOther
Pre-operative metabolic inflexibility will be assessed as an observational exposure using data from routine pre-operative cardiopulmonary exercise testing (CPET). CPET-derived measures of substrate utilisation, including fat and carbohydrate oxidation, will be used to evaluate the participant's ability to switch between energy sources during physiological stress. Additional blood-based metabolic, immune, and cardiac biomarker analyses may be used to further characterise metabolic phenotype. No treatment, procedure, or clinical management will be assigned or altered by the study.
| Study group | Role | What they receive |
|---|---|---|
| Major Abdominal Cancer Surgery Cohort | Adults aged 18 years and over who are scheduled to undergo major elective abdominal cancer surgery and are already referred for routine pre-operative cardiopulmonary exercise testing (CPET). This is an observational cohort study; no study-specific treatment or intervention will be assigned. Participants will continue with their usual surgical and perioperative care. The study will collect additional blood samples, imaging assessments, CPET-derived metabolic data, wearable activity data, and routine clinical information to evaluate whether pre-operative metabolic inflexibility is associated with myocardial injury after non-cardiac surgery. Receives: Other: Pre-operative Metabolic Inflexibility |
What is being measured
The primary outcome is the main question the study is designed to answer.
Development of Myocardial Injury after Non-Cardiac Surgery
The primary outcome is the number of participants who develop myocardial injury after non-cardiac surgery (MINS) within 72 hours after surgery. MINS means evidence of heart muscle injury after an operation that is not heart surgery. It will be assessed using blood tests for high-sensitivity cardiac troponin I, a protein that is released into the blood when the heart muscle is injured. Blood samples will be taken on postoperative days 1, 2, and 3. Participants will be classified as having MINS if their postoperative troponin result is above the study-defined threshold for myocardial injury and the injury is judged to be related to the perioperative period rather than another clear non-surgical cause.
Measured: From surgery to 72 hours post surgery
Secondary outcomes (4)
Clavien-Dindo Complication Grade
Postoperative complications will be classified using the Clavien-Dindo grading system, which grades complications according to the treatment required to manage them. Higher grades indicate more serious complications. The outcome will report the number of participants with major postoperative morbidity, defined as a Clavien-Dindo grade III or higher complication.
Measured: From surgery to 30 days after surgery
Post-Operative Morbidity Survey (POMS)
Postoperative morbidity will be assessed using the Postoperative Morbidity Survey (POMS), a structured assessment that records whether participants have complications affecting different organ systems after surgery. The outcome will report the number of participants with postoperative morbidity identified by POMS assessment.
Measured: Postoperative day 7
Length of Hospital Stay
Length of hospital stay will be measured as the number of days from the date of surgery to the date the participant is discharged from hospital. This outcome will describe how long participants remain in hospital after their operation.
Measured: From surgery up to hospital discharge, an expected average of 7 days after surgery
Days Alive and Out of Hospital at 90 Days
Days alive and out of hospital at 90 days, also known as DAOH90, will be measured as the number of days the participant is alive and not admitted to hospital during the first 90 days after surgery. This outcome reflects postoperative recovery by combining survival, length of initial hospital stay, and any hospital readmissions within 90 days.
Measured: From surgery to 90 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Oct 2030 (estimated)
- Study completion1 Oct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MINSStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- John Whittle, MBBS, PhD, Principal investigator, University College, London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07694453
- Sponsor's protocol ID
- 200495
- Other IDs
- CC-I23-213-CIPHER-2, 363389
- Acronym
- POM-MIMICS
- Status last verified
- Jul 2026
- First submitted
- 25 Jun 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be made publicly available. The study involves clinical data and blood-derived biomarker data from patients undergoing cancer surgery, and data sharing is restricted by participant confidentiality, consent, and data protection requirements. Results will be reported in aggregate form so that individual participants cannot be identified.